Early-phase development strategies for navigating regulatory complexity in the EU
Insightful regulatory strategy is foundational to any clinical development program. And while we encounter complexities in every region, sponsors say the work of interpreting and addressing regulatory guidance is particularly challenging right now in the European Union (EU). Three recent regulations — Clinical Trial Regulation 536/2014 (EU-CTR), Medical Devices Regulation 2017/745 (EU-MDR), and In Vitro Diagnostics Regulation 2017/746 (EU-IVDR) — require sponsors to follow new processes and have resulted in delays in initiating clinical trials. This has prompted some companies, particularly non-European biotechs, to consider moving early-phase development out of the region.
We’re sensitive to the pressures that sponsors face. Conducting trials in North America, the U.K., or the Asia-Pacific region could make study launch simpler in the short term. But Europe is one of the world’s largest pharmaceutical markets, so we urge sponsors to consider long-term impacts of shifting away from the EU.
Related Insights
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Related Insights
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022